Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 23, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

New developments in the field of diffuse large cell lymphoma.

Fernando Cabanillas¹

¹Auxilio Cancer Center, Hospital Auxilio Mutuo, San Juan, Puerto Rico 00927, USA. fcabanil@mdanderson.org

Hematology (Amsterdam, Netherlands)

|April 18, 2012

Summary

This update covers new developments in Diffuse Large B-cell Lymphoma (DLCL), focusing on subtypes, emerging entities like double hit lymphoma, and breast implant-associated anaplastic large cell lymphoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

Same author

Clinical Features and Therapeutic Outcomes Comparing Primary Mediastinal Large B-cell Lymphoma to Mediastinal Hodgkin Disease.

Puerto Rico health sciences journal·2024

Same author

An Unexpected Presentation of a Maxillary Non-Hodgkin Lymphoma in an Elderly Hispanic Patient.

Puerto Rico health sciences journal·2023

Same author

Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19.

medRxiv : the preprint server for health sciences·2021

Same author

Home-based management of COVID-19 by identification of low-risk features.

medRxiv : the preprint server for health sciences·2021

Same author

Prevalence of Complementary/Alternative Medicine use in Cancer Patients in a Tertiary Hospital in Puerto Rico.

Puerto Rico health sciences journal·2020

Area of Science:

Hematology
Oncology
Pathology

Background:

Diffuse Large B-cell Lymphoma (DLCL) is a significant B-cell malignancy.
DLCL subtypes arise from germinal center or non-germinal center B lymphocytes, impacting prognosis.
Understanding these origins is crucial for effective patient management.

Purpose of the Study:

To review recent advancements impacting DLCL understanding and management.
To discuss the distinctions between germinal center and non-germinal center DLCL.
To highlight newly recognized entities and their clinical relevance.

Main Methods:

Literature review of recent developments in DLCL.
Discussion of pathogenetic differences between DLCL subtypes.
Description of novel DLCL-related entities.

Related Experiment Videos

Last Updated: May 23, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Main Results:

New insights into DLCL pathogenesis and classification are emerging.
Distinct clinical and molecular features differentiate DLCL subtypes.
Emerging entities like double hit lymphoma and borderline lymphomas require specific consideration.

Conclusions:

Recent advances are refining the understanding of DLCL heterogeneity.
The classification and management of DLCL are evolving with new entity recognition.
This update provides a comprehensive overview for clinicians managing DLCL patients.